Skip to content
  • Sunday, 26 July 2026
  • 2:59 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Lilly’s $7bn Acquisition of Kelonia Bears Fruit as In Vivo Cell Therapies Show Significant Promise at ASCO 2026
Pharmaceutical R&D

Lilly’s $7bn Acquisition of Kelonia Bears Fruit as In Vivo Cell Therapies Show Significant Promise at ASCO 2026

Teuku Ryan Jun 3, 2026 0

The American Society for Clinical Oncology (ASCO) meeting in 2026, a cornerstone event for oncological advancements, has concluded, leaving behind…

Read More
Pharmaceutical R&D

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma – Pharmaceutical Technology

Teuku Ryan Jun 2, 2026 0

The rapidly evolving landscape of multiple myeloma treatment is witnessing a pivotal moment with the emergence of in vivo chimeric…

Read More
Pharmaceutical R&D

Eli Lilly Expands In Vivo Gene Therapy Arsenal with $7 Billion Acquisition of Kelonia Therapeutics

Teuku Ryan Apr 21, 2026 0

Eli Lilly and Company has significantly bolstered its position in the rapidly evolving cell and gene therapy (CGT) landscape with…

Read More
Pharmaceutical R&D

The Dawn of In Vivo Cell Therapies: A New Era in Precision Medicine Unfolds Amidst Significant Investment and Innovation

Teuku Ryan Apr 18, 2026 0

The pharmaceutical landscape is witnessing a profound transformation with the ascendance of in vivo cell therapies, a revolutionary approach that…

Read More
The biggest problem with solid-state batteries may finally be solvedNovartis Acquires Promising Breast Cancer Drug SNV4818 from Synnovation Therapeutics for Up to $3 BillionExtra Virgin Olive Oil Consumption Linked to Enhanced Gut Microbiome Diversity and Preservation of Cognitive Function in Aging AdultsScience News: Empowering Public Understanding of Science Since 1921
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ